These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17652815)

  • 1. Molecular and cellular mechanisms of anthracycline cardiotoxicity.
    Chen B; Peng X; Pentassuglia L; Lim CC; Sawyer DB
    Cardiovasc Toxicol; 2007; 7(2):114-21. PubMed ID: 17652815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection?
    Sawyer DB; Peng X; Chen B; Pentassuglia L; Lim CC
    Prog Cardiovasc Dis; 2010; 53(2):105-13. PubMed ID: 20728697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine.
    Peng X; Chen B; Lim CC; Sawyer DB
    Mol Interv; 2005 Jun; 5(3):163-71. PubMed ID: 15994456
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New iron chelators in anthracycline-induced cardiotoxicity.
    Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
    Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic anthracycline cardiotoxicity: molecular and functional analysis with focus on nuclear factor erythroid 2-related factor 2 and mitochondrial biogenesis pathways.
    Jirkovsky E; Popelová O; Kriváková-Stanková P; Vávrová A; Hroch M; Hasková P; Brcáková-Dolezelová E; Micuda S; Adamcová M; Simůnek T; Cervinková Z; Gersl V; Sterba M
    J Pharmacol Exp Ther; 2012 Nov; 343(2):468-78. PubMed ID: 22915767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anthracycline cardiotoxicity in long-term survivors of childhood cancer.
    Scully RE; Lipshultz SE
    Cardiovasc Toxicol; 2007; 7(2):122-8. PubMed ID: 17652816
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cardiotoxicity of anthracyclines].
    Costache II; Petriş A
    Rev Med Chir Soc Med Nat Iasi; 2011; 115(4):1200-7. PubMed ID: 22276470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 4'-Epidoxorubicin to re-explore anthracycline degradation in cardiomyocytes.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2009 Jun; 22(6):978-83. PubMed ID: 19397277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deferiprone does not protect against chronic anthracycline cardiotoxicity in vivo.
    Popelová O; Sterba M; Simůnek T; Mazurová Y; Guncová I; Hroch M; Adamcová M; Gersl V
    J Pharmacol Exp Ther; 2008 Jul; 326(1):259-69. PubMed ID: 18434588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anthracycline cardiotoxicity in breast cancer patients: synergism with trastuzumab and taxanes.
    Gianni L; Salvatorelli E; Minotti G
    Cardiovasc Toxicol; 2007; 7(2):67-71. PubMed ID: 17652806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity.
    Sawyer DB; Zuppinger C; Miller TA; Eppenberger HM; Suter TM
    Circulation; 2002 Apr; 105(13):1551-4. PubMed ID: 11927521
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage.
    Geisberg CA; Sawyer DB
    Curr Hypertens Rep; 2010 Dec; 12(6):404-10. PubMed ID: 20842465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anthracycline degradation in cardiomyocytes: a journey to oxidative survival.
    Menna P; Salvatorelli E; Minotti G
    Chem Res Toxicol; 2010 Jan; 23(1):6-10. PubMed ID: 19954191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity.
    de Korte MA; de Vries EG; Lub-de Hooge MN; Jager PL; Gietema JA; van der Graaf WT; Sluiter WJ; van Veldhuisen DJ; Suter TM; Sleijfer DT; Perik PJ
    Eur J Cancer; 2007 Sep; 43(14):2046-51. PubMed ID: 17719768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention.
    Henriksen PA
    Heart; 2018 Jun; 104(12):971-977. PubMed ID: 29217634
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure to anthracyclines during childhood causes cardiac injury.
    Lipshultz SE
    Semin Oncol; 2006 Jun; 33(3 Suppl 8):S8-14. PubMed ID: 16781284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genotyping the risk of anthracycline-induced cardiotoxicity.
    Deng S; Wojnowski L
    Cardiovasc Toxicol; 2007; 7(2):129-34. PubMed ID: 17652817
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of chronic anthracycline cardiotoxicity in the adult Fischer 344 rat by dexrazoxane and effects on iron metabolism.
    Cusack BJ; Gambliel H; Musser B; Hadjokas N; Shadle SE; Charlier H; Olson RD
    Cancer Chemother Pharmacol; 2006 Oct; 58(4):517-26. PubMed ID: 16555089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antioxidant defense against anthracycline cardiotoxicity by metallothionein.
    Kang YJ
    Cardiovasc Toxicol; 2007; 7(2):95-100. PubMed ID: 17652812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity of cytotoxic drugs.
    Schimmel KJ; Richel DJ; van den Brink RB; Guchelaar HJ
    Cancer Treat Rev; 2004 Apr; 30(2):181-91. PubMed ID: 15023436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.